[A13-35] Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 02.01.2014
Project no.:
A13-35
Commission:
Commission awarded on 24.09.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-59 | Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-17 | Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-39 | Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A14-10 | Addendum to Commission A13-35 (dabrafenib) | Commission completed |
| G24-07 | Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11 | Commission completed |